Costa Célia Maria, Pedrosa Sílvia Santos, Kirkland James L, Reis Flávio, Madureira Ana Raquel
Universidade Católica Portuguesa, CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Rua Diogo Botelho 1327, Porto 4169-005, Portugal.
Biorbis, Unipessoal LDA, Edifício de Biotecnologia da Universidade Católica Portuguesa, Rua Diogo Botelho 1327, Porto 4169-005, Portugal.
Ageing Res Rev. 2025 Feb;104:102619. doi: 10.1016/j.arr.2024.102619. Epub 2024 Dec 3.
During the last few decades, life expectancy has increased worldwide along with the prevalence of several age-related diseases. Among aging pathways, cellular senescence and chronic inflammation (or "inflammaging") appear to be connected to gut homeostasis and dysbiosis of the microbiome. Cellular senescence is a state of essentially irreversible cell cycle arrest that occurs in response to stress. Although senescent cells (SC) remain metabolically active, they do not proliferate and can secrete inflammatory and other factors comprising the senescence-associated secretory phenotype (SASP). Accumulation of SCs has been linked to onset of several age-related diseases, in the brain, bones, the gastrointestinal tract, and other organs and tissues. The gut microbiome undergoes substantial changes with aging and is tightly interconnected with either successful (healthy) aging or disease. Senotherapeutic drugs are compounds that can clear senescent cells or modulate the release of SASP factors and hence attenuate the impact of the senescence-associated pro-inflammatory state. Phytochemicals, phenolic compounds and terpenes, which have antioxidant and anti-inflammatory activities, could also be senotherapeutic given their ability to act upon senescence-linked cellular pathways. The aim of this review is to dissect links among the gut microbiome, cellular senescence, inflammaging, and disease, as well as to explore phytochemicals as potential senotherapeutics, focusing on their interactions with gut microbiota. Coordinated targeting of these inter-related processes might unveil new strategies for promoting healthy aging.
在过去几十年间,全球预期寿命有所增加,同时一些与年龄相关的疾病患病率也在上升。在衰老途径中,细胞衰老和慢性炎症(或“炎症衰老”)似乎与肠道内环境稳态及微生物群失调有关。细胞衰老是一种基本不可逆的细胞周期停滞状态,它是对压力的一种反应。虽然衰老细胞(SC)仍保持代谢活性,但它们不会增殖,并且能够分泌包括衰老相关分泌表型(SASP)在内的炎症因子和其他因子。SCs的积累与大脑、骨骼、胃肠道以及其他器官和组织中多种与年龄相关疾病的发生有关。肠道微生物群会随着年龄增长发生显著变化,并且与成功(健康)衰老或疾病紧密相连。衰老治疗药物是能够清除衰老细胞或调节SASP因子释放从而减轻衰老相关促炎状态影响的化合物。具有抗氧化和抗炎活性的植物化学物质、酚类化合物和萜类化合物,鉴于它们作用于与衰老相关细胞途径的能力,也可能具有衰老治疗作用。这篇综述的目的是剖析肠道微生物群、细胞衰老、炎症衰老和疾病之间的联系,以及探索植物化学物质作为潜在衰老治疗药物的作用,重点关注它们与肠道微生物群的相互作用。对这些相互关联过程的协同靶向可能会揭示促进健康衰老的新策略。